Clinical significance of the LacdiNAc‐glycosylated prostate‐specific antigen assay for prostate cancer detection

To reduce unnecessary prostate biopsies (Pbx), better discrimination is needed. To identify clinically significant prostate cancer (CSPC) we determined the performance of LacdiNAc‐glycosylated prostate‐specific antigen (LDN‐PSA) and LDN‐PSA normalized by prostate volume (LDN‐PSAD). We retrospectivel...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Cancer Sci
Main Authors: Yoneyama, Tohru, Tobisawa, Yuki, Kaneko, Tomonori, Kaya, Takatoshi, Hatakeyama, Shingo, Mori, Kazuyuki, Sutoh Yoneyama, Mihoko, Okubo, Teppei, Mitsuzuka, Koji, Duivenvoorden, Wilhelmina, Pinthus, Jehonathan H., Hashimoto, Yasuhiro, Ito, Akihiro, Koie, Takuya, Suda, Yoshihiko, Gardiner, Robert A., Ohyama, Chikara
Formato: Artigo
Idioma:Inglês
Publicado: John Wiley and Sons Inc. 2019
Assuntos:
Original Articles
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6676104/
https://ncbi.nlm.nih.gov/pubmed/31145522
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.14082
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares